• REZYFi, Inc. is a real estate-oriented mortgage company servicing the needs of both traditional and non-traditional consumers and businesses
• The company operates through its two subsidiaries, REZYFi Lending, which is now focused on cannabis commercial real estate lending, and ResMac, Inc., a traditional mortgage origination, correspondent, and servicing business
• REZYFi seeks to provide access to financial services to the cannabis industry, which is still largely underserved because large financial companies have continuously shied away due to the illegality of cannabis at the federal level
• The US cannabis industry is expected to generate $52.6 billion in sales by 2026, up from an estimated $33 billion in 2022, figures that make it possibly the largest underbanked industry in the country

As of May 2022, 19 states, the District of Columbia, and two US territories – Guam and the Northern Mariana Islands – had legalized the recreational use of marijuana among adults, according to the National Conference of State Legislatures (https://ibn.fm/SbcVu). But federally, the possession and use of cannabis are illegal, as per the Controlled Substances Act of 1970 (“CSA”). And as a Financial Times (“FT”) article reports, cannabis companies had long been caught in the gap between state and federal law. “With top US banks such as JPMorgan Chase (NYSE: JPM) and Wells Fargo (NYSE: WFC) and payment companies including Visa (NYSE: V) and Mastercard (NYSE: MA) adhering to federal law, they have opted out of serving cannabis companies,” the FT article reads (https://ibn.fm/FSpMX). This had long starved cannabis companies of the ability to transact electronically, take out loans, and make deposits. However, the situation is changing for the better thanks to financial services companies like REZYFi that have emerged to cater to the cannabis industry. A real estate-oriented loan origination and servicing company, serving the needs of both traditional and non-traditional consumers and businesses, REZYFi primarily targets licensed and permitted cannabis companies and owners of real estate who lease to cannabis companies. Specifically, the company works to “provide senior loan and project financings to state-licensed operators in the cannabis industry, secured by real estate” and/or other permitted assets. REZYFi, which is led by senior executives with hands-on grasp of and experience in the state-permitted cannabis sectors as well as real estate and mortgage sectors, understands the myriad challenges cannabis companies and property owners who lease to such companies face when looking for real estate or project financing. In fact, the FT article believes the cannabis market, whose combined US medical and recreational sales are expected to reach an estimated $52.6 billion by 2026, up from an estimated $33 billion by the end of 2022 (https://ibn.fm/EoXiY), “can make a credible claim of being the largest underbanked industry in the US.” As companies like REZYFi try to fill this vacuum, providing access to financial services that the cannabis industry desperately needs, some fund managers cited in the article believe that “companies targeting this problem are among the most compelling businesses in the industry from an investment standpoint.” Moreover, the investment value proposition is boosted even further by REZYFi’s expectation that the “limited access to the mainstream banking and non-bank financing industry [will] continue for the foreseeable future.” Licensed in 36 states and headquartered in Miami, Florida, REZYFi operates through its two subsidiaries: REZYFi Lending, which is now focused on cannabis commercial real estate lending, and ResMac, Inc., a traditional mortgage origination, correspondent, and servicing business. In addition to targeting the state-licensed cannabis companies, REZYFi also offers financial services to companies and individual homeowners looking for a variety of real estate-related first and additional mortgage-based financing and project-specific financings. For more information, visit the company’s website at www.REZYFi.com. NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://ibn.fm/REZY

• Odyssey Health is a medical company focused on unique, life-saving medical products that offer clinical advantages to unmet clinical needs
• With concussion representing a high unmet need as there is currently no FDA-approved drug, Odyssey is developing a drug formulation, PRV-002, to be administered to concussed patients; the drug candidate is currently undergoing clinical evaluation
• In a recent announcement, the company reported the successful completion of its Phase I clinical trial, which showed that the drug was safe and well tolerated
• Odyssey is looking to present the findings of the Phase I study to the FDA and is also preparing for the planned Phase II trial

A soft and squishy organ that can be deformed with a simple touch, the human brain is extremely sensitive. And although it is encased in a sturdy skull and surrounded by a cushioning fluid that collectively work to protect it from the external environment and forces that could easily wreak havoc, it is still vulnerable to extremities. In fact, blows, jolts, violent shaking, or rapid decelerations as a result of an accident, for example, can and do override these protections, leading to a mild form of brain injury called mTBI or concussion or mTBI, an area of interest for medical company Odyssey Health (OTC: ODYY). Concussion Effects After a concussion, and depending on the concussed individual, the brain undergoes changes triggered by, among others, mechanical damage to neuronal connections, chemical imbalance, and activation of inflammation-inducing immune cells (https://ibn.fm/L7YoI), which cause such harmful responses as swelling, inflammation, and oxidative stress. mTBI also decreases blood flow to the brain, restricting glucose from traveling to the cells. To the concussed patient, these changes manifest in the form of symptoms such as dizziness, blurry vision, nausea and vomiting, headache, confusion, and, in some cases, loss of consciousness (https://ibn.fm/b1RKt). While most of these symptoms resolve over the course of several weeks to a few months, concussions can cause long-term consequences. For one, a single concussion raises the risk of having another concussion, with the second being more severe (https://ibn.fm/XFZaE). Relatedly, repetitive concussions are associated with the increased likelihood of developing neurodegenerative conditions such as Parkinson’s and Alzheimer’s disease, as well as chronic traumatic encephalopathy (“CTE”) (https://ibn.fm/Zhf00). PRV-002 Drug-Device Combination With the concussion space representing a high unmet medical need, given there is currently no FDA-approved drug for the condition, Odyssey Health took the initiative to develop one, guided by the need to nip the harmful responses in the bud before they can trigger severe symptoms. The outcome was PRV-002, a fully synthetic, non-naturally occurring neurosteroid. The drug formulation is designed to be administered into the upper nasal cavity a few minutes after a concussion, using the company’s patent-pending intranasal delivery device for onward travel to the brain along the cranial nerve. This route of administration, coupled with the drug’s lipophilic characteristics, enables PRV-002 to cross the blood-brain barrier within five minutes and spread throughout the brain within 30 minutes, reversing the harmful responses. PRV-002 has been the subject of ongoing clinical trials as part of a drug development program that, so far, has included preclinical animal studies and a clinical study. Animal studies evidenced that PRV-002 rapidly eliminates swelling, oxidative stress, and inflammation (https://ibn.fm/7ewOr). Motivated and having fulfilled FDA requirements, Odyssey embarked on the clinical human trial stage, announcing early last Fall that it had begun enrolling subjects for a Phase I trial to treat concussion (https://ibn.fm/p7BjD). Successful Phase I Clinical Trial In a recent news release published September 28, Odyssey reported the successful completion of this Phase I clinical trial, noting that the drug was safe and well tolerated throughout the study period (https://ibn.fm/CnRYO). The trial, a double-blinded, randomized, and placebo-controlled study that comprised a total of 40 healthy human volunteers, was segmented into two stages: Single Ascending Dosing (“SAD”) and Multiple Ascending Dosing (“MAD”). The SAD stage consisted of 24 participants who were separated into three different groups, known as cohorts, and received varying doses of the drug at a ratio of 3:1 with placebo. (The treatment groups were given a low, medium, or high-single dose of PRV-002.) The MAD portion of the trial was made up of 16 subjects, separated into two cohorts, each with eight members. Each subject received a single low or high dose for five consecutive days. The Safety Review Committee (“SRC”) then monitored the subjects after the dosing of each cohort was complete. No adverse events were noted as the drug was well-tolerated for all the cohorts. Vital signs, EKG readings, sleep patterns, and breathing functions were all normal throughout the study, while blood samples showed no alterations associated with the PRV-002 treatment. Moreover, pharmacokinetic analysis, which revealed significantly lower levels of PRV-002 in the blood than what would be expected with other routes of administration, suggested a greater delivery of the drug formulation to the brain. “After reviewing the data from each of the cohorts, I have strong confidence that it is safe to proceed to the next clinical trial phase where PRV-002 will be administered for ten consecutive days to subjects following concussion,” commented Dallas Hack, MD, member of the SRC. “Of particular note, the overall low levels of PRV-002 in the blood supports the hypothesis that more drug is getting to the brain itself when administered with the intranasal device. Less systemic exposure with this targeted approach promotes patient safety.” Odyssey is currently communicating with the FDA to present the findings from the Phase I trial while simultaneously preparing for the planned Phase II trial. More specifically, the company is identifying the Phase II trial sites and is working with its medical advisors to create a study design. For more information, visit the company’s website at www.OdysseyHealthInc.com. NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

• Silo Pharma, Inc recently uplisted to the Nasdaq Capital Market, raising gross proceeds of $5 million
• The biopharmaceutical company has sought to merge traditional therapeutics and psychedelic research, entering into a series of joint ventures with leading medical universities to carry out research into the field
• Meanwhile, psychedelics are gaining increasing favour within the United States with Oregon set to begin allowing the supervised usage of psilocybin from 2023 onwards

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused around merging traditional therapeutics with psychedelic research, recently announced that it had successfully priced its fully underwritten initial public offering, raising gross proceeds of $5 million dollars through the sale of one million shares of its common stock. Furthermore, the company revealed that it had granted a 45-day option to its underwriter to purchase up to an additional 150,000 shares of common stock to cover over-allotments, if any.  Following the offering and as of September 27, 2022, the company’s common stock listed on the Nasdaq Capital Market and commenced trading under the ticker symbol “SILO” (https://ibn.fm/mmEsK). Originally founded in 2010, Silo Pharma has distinguished itself amongst peers for its ground-breaking research into conditions such as post-traumatic stress disorder (“PTSD”), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. Increasingly and over the past two decades, clinical research on psychedelics, most notably psilocybin and methylenedioxymethamphetamine (“MDMA”), has steadily progressed from pilot studies confirming safety and feasibility, through to early phase trials providing preliminary evidence of clinical efficacy. Silo Pharma has been an early pioneer of these research studies through its commitment to develop innovative solutions to address a variety of underserved conditions, many of which are being carried out in partnership with leading medical universities across the globe. In one such instance, Silo Pharma has looked to engage in a sponsored study with the Netherland’s Maastricht University, examining the effect on repeated low doses of ketamine and psilocybin on cognitive and emotional dysfunctions resulting from Parkinson’s disease. Separately, the company has also entered into agreements with the University of California San Francisco (“UCSF”) to determine the effects of psilocybin on inflammation; with the University of Maryland, Baltimore to explore a novel invention known as joint-homing peptides; as well as simultaneously signing an agreement with Columbia University, granting it an option to license a number of assets under development including a prophylactic treatment for stress-induced disorders and PTSD. Although the use of psychedelics has been prolific amongst indigenous populations around the world for hundreds of years, recent medical studies have increasingly shown that psilocybin – a naturally occurring psychedelic prodrug produced within various species of fungi, along with other psychedelics, could have beneficial effects for a variety of mental health related conditions. This movement was further reinforced in 2018, when the U.S. Food and Drug Administration labelled psilocybin a “breakthrough therapy” in treatment for severe depression, a designation the agency applies to drugs that in early trials demonstrate substantial improvement over existing treatments (https://ibn.fm/bX5PY). In 2020, Oregon voters approved a ballot measure which paved the way for the state to put in place a legislative framework which, starting in 2023, will enable patients to take psilocybin under supervision (https://ibn.fm/FurGl). Following on from Oregon’s pioneering actions, Texas, Utah, and Washington State have all set up task forces or funded research into the medical use of psilocybin. Meanwhile, Maryland has created a $1 million fund to study alternative treatments, including psychedelics, for PTSD or traumatic brain injury, and to pay for such treatments for veterans. With psilocybin and psychedelic-based therapeutic treatment increasingly gaining favour amongst the medical community and with a rising prevalence of depression and mental disorders within modern society, forecasts have now projected the psychedelic drugs market to swell to a value of $6.8 billion annual by 2027, representing a CAGR of 16.3% within the forecast period of 2020 to 2027 (https://ibn.fm/qMaaq). Through their recent NASDAQ uplist and various research and drug developmental initiatives, Silo Pharma have sought to position themselves at the forefront of the psychedelic revolution currently affecting the medical field. “After the exciting progress we have made over the last year, uplisting to the NASDAQ is the next strategic step for Silo Pharma. A NASDAQ listing should provide greater liquidity for our investors, attract institutional investors, increase the visibility of the company and raise our overall profile,” said Eric Weisblum, CEO of Silo Pharma. For more information, visit the company’s website at www.SiloPharma.com. NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

• Mullen and Watergen are together developing technology to produce fresh drinking water from the air for in-vehicle consumer and commercial application
• Opportunities for air-to-water vehicle applications are endless, and Mullen is proud to work with Watergen on this game-changing technology
• This innovative tech is envisioned for Mullen’s fleet of EV cargo vans and can be utilized in both commercial and recreational vehicle settings

A Car and Driver article points to climbing sales in the U.S. electric vehicle space as one of the signs that the country is accepting EVs (https://ibn.fm/2BclA). This growing acceptance is fueling Mullen Automotive (NASDAQ: MULN) commitment to make EVs more accessible than ever (https://ibn.fm/0sTw0). As evidence of that focus, Mullen recently announced a partnership with Watergen Inc. to develop and equip Mullen’s portfolio of electric vehicles with technology that will produce fresh drinking water from the air for in-vehicle consumer and commercial application. “Our partnership with Watergen has been months in the making and is a very exciting opportunity for both our companies,” said Mullen Automotive CEO and chair David Michery. “Mullen will be the first automotive company to codevelop this technology with Watergen for our entire portfolio of electric vehicles. The opportunities for air-to-water vehicle applications are endless, and Mullen is proud to partner with Watergen on this game-changing technology.” According to the company, Watergen is an Israel-based company and a global pioneer in the atmospheric drinking water devices (“AWG”) market, building technology and equipment that create drinking water from the air. “The company’s solutions are the most effective and economical way to solve the pressing issue of drinking water scarcity in any location, at any time, and to enable the elimination of carbon-intensive supply chains and environmentally harmful plastic waste,” the announcement stated. “Watergen’s technology of ‘air to clean drinking water’ for vehicles can generate a fresh supply of hot and cold drinking water for vehicle occupants,” the statement continued. “This technology is envisioned for Mullen’s fleet of EV cargo vans and can be utilized in both commercial and recreational vehicle settings. The air-to-water systems will provide up to five liters of drinking water daily, directly from the air, while the vehicle is moving and can be used as a fresh water source for the vehicle occupants.” The partnership has been in the making for several months. Mullen has been one of Watergen’s design partners for in-vehicle, air-to-water technology, with the goal of Mullen initiating vehicle testing of the new service in Q1 2023. “The cooperation with Mullen takes us another step towards a cleaner environment and a unique and uncompromising vehicle experience,” said Watergen vice president of mobility Steve Elbaz. “We are working and will continue to work for a clean future — not just for us but for every person in this world.” Mullen is a Southern California–based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. The company’s current EV development portfolio includes the Mullen FIVE EV Crossover, the Mullen ONE EV Fleet Vans and the DragonFLY Sports Car. The company has evolved over the past decade in sync with consumers and technology trends. Today, MULN is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. For more information about the company, visit www.MullenUSA.com. NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

• Louisiana-based Correlate Infrastructure Partners Inc. provides commercial industry solutions for reducing climate-averse energy use and pollutant emissions, drawing on Correlate’s data-driven analysis and experienced financial resources analysis
• The United States’ recently passed Inflation Reduction Act was a governmental effort to create incentives for greater renewable energy adoption, and CIPI anticipates a resulting tailwind effect for the company’s efforts to promote climate responsibility
• Many companies are using environmental, social and governance (“ESG”) reports to identify their approach to climate-friendly action in a transparent manner
• CIPI can draw on its experience to help clients avoid charges of “greenwashing” their ESG reports as a growing number of companies come under criticism for how they present their environmental friendliness

Economic worries have underscored news-of-the-moment reports for months as food and energy prices have soared, employment fatigue has hampered retailers and another season has brought its share of punishing weather conditions. U.S. Treasury Secretary Janet Yellen, responsible for translating the government’s directives into policy that manages the public debt and sustains the economy, stated in a recent interview that advances in the adoption of renewable energy such as the newly passed Inflation Reduction Act (“IRA”) will ultimately help strengthen the nation’s economy through energy security (https://ibn.fm/JCQs1). Clean energy solutions innovator Correlate Infrastructure Partners (OTCQB: CIPI) applauded the IRA as a means of providing consumers with great incentives for changing their customary approach to energy use toward more greenhouse gas-reducing options as financial assistance to climate-friendly companies trickles down. “The historic climate bill includes several initiatives that will provide long-term stability and incentives to the U.S. renewable energy industry,” Correlate Infrastructure Partners CEO Todd Michaels stated in an August news release (https://ibn.fm/tB5F3). “This includes an increase and extension of the investment tax credit for solar and storage and a more flexible structure for companies like Correlate to monetize that tax credit. These two key proposals have the potential to accelerate Correlate’s growth, support our ability to own and operate nationwide solar and storage assets, and contribute to strengthening the economy through clean energy project deployment.” Correlate, also known as CIPI, helps clients improve the ways their commercial buildings use energy by evaluating current energy use, anticipating potential ways to reduce their energy use and pollutants, and identifying ways to finance the transition and make the climate-friendly changes as affordable as possible. These changes in turn have the potential to reduce the degree to which state power grids are taxed during severe weather events, creating the potential for improved emergency response to such situations. “Once we identify the right mix of energy upgrades for a given property or portfolio, we then provide all the capital to deploy those technologies and maintain them over time including monitoring these facilities on a 24/7 basis,” Michaels stated in a September interview posted on the company’s website (https://ibn.fm/m5HVd). “Ongoing maintenance is very complex and even some of the most sophisticated facility management companies don’t have the resources to effectively manage it.” While commercial industries have increased their use of environmental, social and governance (“ESG”) reporting to provide quality of life-conscious consumers with a measurable standard for judging the value of companies beyond their financial net worth, consumers and regulators still need to exercise caution in evaluating businesses’ transparency and the possibility they may be “greenwashing” their performance reports, a Sept. 21 CNBC report argued. “The debate surrounding greenwashing is becoming increasingly fierce, with the charge often leveled at multinational companies with vast resources and significant carbon footprints,” the report stated (https://ibn.fm/IU7zS). In addition to greenwashing investigations of companies by regulatory agencies such as the U.S. Securities and Exchange Commission (“SEC”) and criminal prosecutors in Germany (https://ibn.fm/0mcrw), a number of environmental organizations joined together in filing a lawsuit this summer against aviation giant KLM, showing the resources at their disposal to battle ESG claims they consider questionable (https://ibn.fm/uQjJM). CIPI’s expertise and resourcefulness can help industry clients boost their ESG profiles and avoid negative greenwashing publicity from critics. For more information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• The 28 home Geos neighborhood in Arvada, Colorado has distinguished itself for its provision of net-zero-energy, green homes
• The homes used technology akin to that provided by GeoSolar Technologies’ SmartGreen(TM) Home System
• The SmartGreen(TM) Home System has sought to make the average American home environmentally friendly whilst satisfying its energy requirements entirely through renewable energy sources – slashing utility bills close to zero in the process

In 2015, Dar-Long Chang quit his 15-year career with ExxonMobil after coming to the realization that oil and gas was not a sustainable industry – a decision whose foundations lay well in the past, when Hurricane Ike impacted the city of Houston in 2008. The tropical cyclone made landfall on September 13, 2008, ravaging the state of Texas with sustained winds upwards of 110 miles per hour (“mph”). The hurricane would go on to damage over eighty percent of Houston’s homes and infrastructure, whilst knocking out power to over three million Texans by one count. Dar-Lon Chang attributed the disaster to climate change. Years later, when he made the decision to quit ExxonMobil, Chang looked for an environmentally friendly home, one which would be both, energy sufficient and help contribute to a Net Zero future. What he found was the Geos Neighborhood in Arvada, Colorado (https://ibn.fm/wwXvl). Homes powered by renewable energy have long been dismissed by developers and consumers as an unrealistic ideal; developers would remark on the elevated upfront costs that such a building would entail (i.e. it costs an average of $18,000 to install a 6kW grid-tied residential solar system) and the lengthy payback period that such an investment would result in (https://ibn.fm/PmVE2). However, Norbert Klebl, the engineer behind the net-zero-energy, 28-home Geos neighborhood argues that the price of going green doesn’t have to be that high. Klebl revealed that the 28 homes required an estimated $20,000 to $25,000 extra in construction costs per home. Moreover, he added, the homes resulted in a 70 percent improvement in energy efficiency whilst simultaneously, slashing the consumption of fossil fuel-based energy to zero. It is exactly this kind of vision that GeoSolar Technologies (“GST”), a Colorado-based climate technology company which provided the systems underpinning the Geos Neighborhood, is now looking to bring to fruition at a grander scale. Through the introduction of its proprietary Smart Green Home system – an environmentally friendly, renewable energy focused technology designed to harness energy from the earth and sun to power and purify homes and automobiles without the use of fossil fuels, GeoSolar have looked to tackle the astounding thirty percent of global greenhouse gases generated by households every year. Moreover and during a time of increasingly elevated electricity costs, the company revealed that the average GeoSolar-powered home could result in a negligible carbon footprint with homeowners disbursing less than $100 per annum in utility bills  (https://www.geosolarplus.com/geosolarplus). Whilst the installation of solar panels and geothermal heat pumps have played an important role in the construction of a GeoSolar Technologies-powered home, the Company has sought to adopt a more holistic approach towards energy conservation and the achievement of a carbon-free future. Homes are oriented with large, south-facing windows, thereby attracting sunlight in the wintertime. Houses are also created with ‘tighter shells’ and triple-paned windows to avoid leakages; as Geos engineer Norbert Klebl noted, the average American home exchanged upwards of 100 percent of its interior air every five hours through leakages alone. Finally, the homes would be conditioned with a unique air circulation system, recirculating air through air and heat pumps to heat and cool homes rather than relying on traditional air-conditioning and gas furnace systems. Although Klebl acknowledged that some people could view the heat pumps as a “mystery” given the rarity of the technology within American homes and their temperature regulation systems, he did point out that it was relatively commonplace. Nearly every household in American had a heat pump in the form of a refrigerator he noted, designed to keep the interior cold, and heat out. A recent study carried out by Consumer Affairs found that seventy percent of American homeowners reported an increase in home value following the installation of solar panels, with three out of four homeowners stating that they would not buy their next home if the property did not boast solar or some type of eco-friendly feature. With sustainable living and renewable energy provision increasingly on the minds of homeowners, GeoSolar Technologies has sought to position itself to assist with the green revolution soon to hit American shores. For more information, visit the company’s website at www.GeoSolarPlus.com. NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST

• Flora just announced the first successful export of Colombian high-CBD dried cannabis flower to Switzerland and the Czech Republic, as well as CBD isolate to the United States
• Luis Merchan, the company’s CEO, has described this as a “major milestone,” one that further defines the company’s revenue pipeline
• He pointed out the increasing demand for Flora’s high-quality, high-margin flower and derivatives from its cultivation operation in Colombia, terming it as a testament to the Flora team’s ability to execute in a very complex global regulatory environment
• Flora also earned the Best M&A Deal award at Benzinga’s 2022 Cannabis Capital Conference in Chicago, an award that recognized the company’s strategic M&A objectives, including acquiring products, expertise, expanding distribution, and customers

On September 26, Flora Growth (NASDAQ: FLGC) announced the first successful export of Colombian high-CBD dried cannabis flower to Switzerland and the Czech Republic, as well as CBD, isolate to the United States. Luis Merchan, Chairman and Chief Executive Officer (“CEO”) of the company, described this as a “major milestone,” one that further defines Flora’s revenue pipeline. The company also launched its commercial website, where interested buyers can expedite the processing of orders and learn about the company’s cultivation and growth practices (https://ibn.fm/3u3DW). With the global CBD market having achieved impressive growth thus far and showing even greater potential growth in the coming years, Flora is positioning itself as a key industry player, looking to take advantage of this development. The sector is projected to be valued at US$47 billion by 2028, up from US$4.9 billion in 2021 (https://ibn.fm/vlu4Y). This growth will be primarily attributed to an overall shift in policy on CBD programs in key markets, with countries such as Switzerland announcing pilot projects to open adult-use cannabis sales to test the viability of a fully legal recreational market. “As our global distribution network continues to evolve, adding these three industry-leading countries to our footprint is a major milestone for Flora,” noted Mr. Merchan. “Our cultivation operation in Colombia, which provides high-quality, high-margin flower and derivatives, has experienced increasing demand. These exports are a testament to our team’s ability to execute in a very complex global regulatory environment and create new commercial revenue for our company,” he added. Flora’s current performance can be attributed to the company’s commitment to diversifying its product line and its team’s resolve to explore new markets. In addition, the company has leveraged strategic acquisitions, including Vessel Brand Inc., Just Brands LLC, and High Roller Private Label LLC, among others, to achieve both short-term and long-term objectives. These efforts have earned Flora the Best M&A Deal award at Benzinga’s 2022 Cannabis Capital Conference held in Chicago. “We are honored to receive the award for Best M&A Deal at the Benzinga Cannabis Capital Conference, which recognizes our strategic M&A objectives, including acquiring products, expertise, expanding distribution, and customers,” noted Mr. Merchan (https://ibn.fm/uqraz). Flora’s acquisitions have enhanced the company’s infrastructure in the United States while allowing it to benefit from widespread distribution across various mainstream U.S. channels. JustCBD’s acquisition, completed in February 2022, for instance, expanded the company’s portfolio by over 300 products and opened the company up to over 300,000 customers. “This acquisition continues to strengthen Flora’s foothold in the U.S. wellness market as well as providing meaningful growth acceleration and delivering human capital to the Flora organization,” noted Mr. Merchan during the announcement of the JustCBD acquisition (https://ibn.fm/DUz4l). For more information, visit the company’s website at www.FloraGrowth.com. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• More than a dozen cannabis reform bills were passed by the California legislature during the summer
• Governor Newsom signed 10 of the bills
• SGMD is focused on strengthening its presence in a variety of spaces, including cannabis

As the California legislature ended its session last month, more than a dozen cannabis reform bills were approved and sent to Governor Gavin Newsom for his consideration (https://ibn.fm/TLbMU); ultimately, the governor signed 10 of them (https://ibn.fm/HOL7u). The show of government support for cannabis in the state bodes well for California cannabis companies, including Sugarmade (OTC: SGMD), a product and branding marketing company investing in operations and technologies with disruptive potential, including cannabis. “For too many Californians, the promise of cannabis legalization remains out of reach,” said Governor Newsom. “These measures build on the important strides our state has made toward this goal, but much work remains to build an equitable, safe and sustainable legal cannabis industry. I look forward to partnering with the legislature and policymakers to fully realize cannabis legalization in communities across California.” A Marijuana Moment article reported that “in the past several weeks, more than a dozen cannabis reform bills crossed the finish line in Sacramento, pending action from Gov. Gavin Newsom.” Included in those bills was one that would prohibit localities from banning medical cannabis deliveries in their areas, “a move that advocates say will both improve patient access and help fill voids throughout the state where no cannabis license types have been authorized,” the article stated. Other bills included a measure providing employment protections for employees who use marijuana during their off hours, a bill designed to streamline record sealing for people with eligible marijuana-related convictions, and legislation that would set the state up to allow interstate cannabis commerce. The full list of bills signed by the governor include the following: AB 1706, cannabis crimes: resentencing; AB 1646, cannabis packaging: beverages; AB 1885 by cannabis and cannabis products: animals: veterinary medicine; AB 1894, integrated cannabis vaporizer: packaging, labeling, advertisement, and marketing; AB 2210, cannabis: state temporary event licenses, venues licensed by the Department of Alcoholic Beverage Control, unsold inventory; AB 2188, discrimination in employment: use of cannabis; AB 2568, cannabis: insurance providers; AB 2925, California Cannabis Tax Fund: spending reports; SB 1186, Medicinal Cannabis Patients’ Right of Access Act; and SB 1326, cannabis: interstate agreements. According to the governor’s office, these bills “build on the administration’s efforts to strengthen California’s cannabis legalization framework. As part of this year’s state budget, the governor signed legislation to provide tax relief to consumers and the cannabis industry; support equity businesses; strengthen enforcement tools against illegal cannabis operators; bolster worker protections; expand access to legal retail; and protect youth, environmental and public safety programs funded by cannabis tax revenue. “To expedite policy reforms that prioritize and protect California consumers’ health and safety, the governor has directed the California Department of Public Health to convene subject matter experts to survey current scientific research and policy mechanisms to address the growing emergence of high-potency cannabis and hemp products,” the governor’s announcement continued. “The governor has also directed the Department of Cannabis Control to further the scientific understanding of potency and its related health impacts by prioritizing the funding of research related to cannabis potency through its existing public university grants.” Sugarmade is focused on strengthening its presence in a variety of spaces, including cannabis. The company is rethinking metrics to leverages its portfolio data to “quickly and intuitively understand what we need to focus on creating today to satisfy customers tomorrow, improving efficiency, profit margins, and top-line sales,” (https://ibn.fm/d6pmP). SGMD’s brand portfolio currently includes CarryOutsupplies.com, SugarRush(TM), NUG Avenue, J Grade Farm, Lemon Glow and Budcars. For more information, visit the company’s website at www.Sugarmade.com. NOTE TO INVESTORS: The latest news and updates relating to SGMD are available in the company’s newsroom at http://ibn.fm/SGMD

• Odyssey successfully completed the second Cohort of its Phase I MAD clinical trial, proving the safety profile of its concussion pharmaceutical treatment, PRV-002
• This study built on the success of Cohort I, where the drug was well tolerated and proved safe, with no severe adverse events reported
• The company’s Phase I Single Ascending Dose (“SAD”) cohorts of the clinical trial closed on July 12, 2022, proving the drug was safe and well tolerated. Results from this study were well received by the SRC, who also expressed their optimism for Odyssey’s completion of the MAD portion of its Phase I trial and subsequent Phase II and III studies
• Odyssey looks to offer a viable solution for treating concussions, regarded as a significant “unmet” medical need. It also looks to capitalize on a growing market projected to be valued at $8.9 billion by 2027

Odyssey Health (OTC: ODYY), an enterprise committed to developing unique, life-enhancing medical products, marked a successful close of the second Cohort of its Phase I Multi-Day Ascending Dosing (“MAD”) clinical trial (https://ibn.fm/pnUwS). While making the announcement, Odyssey’s Chief Executive Officer (“CEO”), Michael Redmond, expressed how pleased he was with the safety profile of the company’s concussion pharmaceutical treatment, PRV-002. “As we come close to completing the Phase I trial, I am very pleased with the safety profile of our concussion pharmaceutical treatment, PRV-002,” he noted. “I’m equally pleased that the intranasal drug/device combination has functioned nicely and has been easy to operate in the clinical setting,” he added. Odyssey’s trial involved administering its novel drug to treat concussions, PRV-002, to healthy human subjects to determine drug safety. A total of 40 healthy subjects took part in the study. In Cohort I, eight patients received a low dose of the drug, and in Cohort II, patients received a high dose of the drug. The second Cohort reflected the success of the first, where the drug was well tolerated and proved safe with no severe adverse events reported. On July 12, 2022, Odyssey announced the successful completion of its Phase I Single Ascending Dosing (“SAD”) clinical trial, which also involved administering PRV-002. This study proved that the drug was safe and well tolerated and would lay the foundation for the currently-ongoing MAD clinical study (https://ibn.fm/vSh7h). At the time, Dallas Hack, the Managing Director (“MD”) and member of the Safety Review Committee (“SRC”), reckoned: “After reviewing the data from Cohort III and completing the SAD analysis, I have strong confidence that PRV-002 will continue to show safety during the Multiple Ascending Dosing (‘MAD’) portion of the Phase I clinical trial where subjects are treated once daily for five straight days.” Philip Ryan, the MD and Principle Investor for Nucleus Network, noted: “PRV-002 was well-tolerated throughout the SAD portion of the Phase I trial. The SRC has confidence about the safety of the intranasal delivery of PRV-002.” “We look forward to completing MAD portion of the Phase I trial and assisting Odyssey with their Phase II/III design to determine the efficacy of PRV-002 for concussed patients,” he added. Odyssey, so far, has lived up to its expectations and those of the SRC, proving the overall safety of its novel drug. With concussions representing a significant “unmet” medical need affecting millions worldwide, the company is inching closer to offering a viable solution that will benefit patients. In addition, it is positioning itself to take advantage of an industry projected to be valued at $8.9 billion by 2027, up from $6.9 billion in 2020 (https://ibn.fm/LNyM3). Odyssey is currently in the process of selecting clinical sites and developing the Investigator’s Brochure for the Phase II trial. As of July 2022, the company was still in discussions with military training sites for Phase II and III clinical trials, which it hopes to kick off later this year. For more information, visit the company’s website at www.OdysseyHealthInc.com. NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

• EverGen Infrastructure Corp. announces upgrade from OTCQB(R) Venture Market to OTCQX market in US; Company’s common shares to be quoted under “EVGIF” symbol
• OTCQX listing provides EverGen increased visibility and access to broader investor audience as company gears up to continue to execute on its ambitious growth plans
• This move comes amid favorable market conditions; global waste-to-energy market is projected to grow at a CAGR of 15.62% and reach USD 103.95 billion by 2027

As renewable natural gas (“RNG”) rapidly transforms from niche fuel to mainstream replacement for conventional natural gas, opportunities open up in the sector and EverGen Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF) appears poised to seize them. After what could be described as a hot streak in which the company embarked on a nationwide expansion, this leading Canadian renewable energy company and renewable natural gas infrastructure platform is gearing up for the next chapter in its growth journey. The company has announced that its common shares were to commence trading on the OTCQX(R) Best Market in the United States under the symbol “EVGIF” (https://ibn.fm/5piOX). For EverGen, this milestone marks an upgrade from the OTCQB(R) Venture Market, where the company’s common shares had been trading since February 2022 (https://ibn.fm/udiEh). After a seven-month stint on this platform reserved for early-stage and developing US and international companies that cannot yet qualify for the most rigorous entry requirements, EverGen progressed toward the top tier OTC market – OTCQX(R) Best Market (OTCQX). The company’s financial disclosure and Real-Time Level 2 quotes are available for US investors at www.OTCMarkets.com. The OTCQX listing helps public companies enhance their liquidity, increase visibility, and expand investor reach, allowing them to diversify their shareholder base through an established, SEC-recognized public market. For example, investors who don’t have access to trading on the TSX Venture Exchange will be able to access EverGen’s common shares through regulated US broker-dealers. “During this milestone rich quarter for EverGen, we are pleased to provide increased access and liquidity for investors in the US who seek to participate in the energy transition,” announced Chase Edgelow, CEO of EverGen. “An upgrade to the OTCQX in the United States is a natural progression for EverGen allowing us to introduce our RNG infrastructure platform to a broader audience as we continue to execute on our growth plans with clear visibility to deliver over 1 million gigajoules of RNG annually,” he concluded. This move comes amid a burgeoning alternative energy market and a strong push for energy transition toward greener solutions, including those based on using waste to create fuel. RNG sector uses organic waste such as food, agriculture, wood, and wastewater that would otherwise release methane, the most potent greenhouse culprit, to produce RNG. As a green energy source interchangeable with conventional natural gas, RNG has the potential to slash carbon emissions in a cost-effective way. Unlike its conventional counterpart, RNG is not a fossil fuel but a clean and affordable waste-derived fuel that can offer a much-needed response to the pressing needs to decarbonize the economy. Landfills are among the biggest sources of methane, a major contributor to global warming, so tackling waste seems pivotal in progressing toward a greener society (https://ibn.fm/80LCs). According to the California Air Resources Board, RNG sourced from landfill-diverted waste can reduce greenhouse gas emissions by 125% (https://ibn.fm/KOoHC). As the international race toward a more climate-friendly economy accelerates, Canada aims to position itself as a global leader in investment in renewable energy. Although many RNG projects are emerging across the country, this may be just the beginning of what is possible in terms of the potential to slash greenhouse emissions. Recent research shows that the global waste to energy market is projected to reach USD 103.95 billion by 2027, growing at a CAGR of 15.62% from USD 50.31 billion in 2022 (https://ibn.fm/U7o1U). In a country that leads when it comes to RNG use, EverGen seems to have emerged as a high-growth pioneer that rapidly expands its footprint across three provinces – from British Columbia, where it had its beginnings, to new projects in Alberta and Ontario. The company remains committed to building reliable infrastructure that aims to turn low-value organic waste into a valuable renewable energy resource and establish itself as an emerging leader in an industry that is yet to flourish. For more information, visit the company’s website at www.EvergenInfra.com. NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF